Alligator Bioscience has just announced that it is carrying out a rights issue worth approximately 257 million SEK. CEO Søren Bregenholt came by the BioStock Studio to discuss the main goals with this capital raise and how Alligator’s lead candidate mitazalimab has become a long-term value driver for the company.
Watch the full interview with Søren Bregenholt below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.